BOCH
SGMT icon

Blue Owl Capital Holdings’s Sagimet Biosciences SGMT Stock Holding History

Blue Owl Capital Holdings’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.74M Buy
1,260,544
+926,667
+278% +$6.3M 1.47% 13
2026
Q1 		$1.74M Sell
333,877
-910,000
-73% -$5.07M 0.47% 33
2025
Q4 		$7.36M Sell
1,243,877
-84,474
-6% -$607K 2.27% 12
2025
Q3 		$9.11M Hold
1,328,351
– – 2.83% 11
2025
Q2 		$10.1M Hold
1,328,351
– – 3.27% 9
2025
Q1 		$4.33M Buy
1,328,351
+4,474
+0.3% +$18.8K 1.4% 19
2024
Q4 		$5.96M Sell
1,323,877
-350,000
-21% -$1.77M 1.37% 18
2024
Q3 		$4.64M Hold
1,673,877
– – 0.89% 26
2024
Q2 		$5.72M Hold
1,673,877
– – 1.59% 18
2024
Q1 		$9.07M Buy
1,673,877
+1,318,500
+371% +$9.47M 1.81% 16
2023
Q4 		$1.93M Buy
+355,377
New +$1.68M 0.46% 30

Other funds holding SGMT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Blue Owl Capital Holdings's SGMT Position: Q2 2026 in Review

Blue Owl Capital Holdings increased its Sagimet Biosciences (SGMT) stake by 278% in Q2 2026, buying an estimated $6.3M and bringing the position to 1,260,544 shares worth $9.74M. The position accounts for 1.47% of the portfolio, ranked #13.

Blue Owl Capital Holdings first reported a position in SGMT in Q4 2023 and has held it in 11 quarters since. The position peaked at $10.1M in Q2 2025. 122 funds tracked by Wall St. Rank hold SGMT as of Q2 2026.

  • Blue Owl Capital Holdings held 1,260,544 shares of Sagimet Biosciences worth $9.74M as of Q2 2026.
  • Blue Owl Capital Holdings bought 926,667 Sagimet Biosciences shares in Q2 2026, an estimated $6.3M.
  • Sagimet Biosciences made up 1.47% of Blue Owl Capital Holdings's portfolio in Q2 2026, its #13 holding.
  • Blue Owl Capital Holdings first reported a position in Sagimet Biosciences in Q4 2023 and has held it in 11 quarters since.
  • Blue Owl Capital Holdings's Sagimet Biosciences position peaked at $10.1M in Q2 2025.
  • 122 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q2 2026.

Based on Blue Owl Capital Holdings's 13F filing for Q2 2026, filed 11 Aug 2026.